10:03 AM EST, 02/04/2025 (MT Newswires) -- (Updates with recent share movement and additional details in the first paragraph and headline.)

Merck ( MRK ) shares were down nearly 11% in recent trading Tuesday after the company said it will not supply its human papillomavirus vaccine Gardasil to China until at least mid-2025 due to weak consumer spending.

The company reported Q4 non-GAAP earnings of $1.72 per share, up from $0.03 a year earlier.

Analysts polled by FactSet expected $1.61.

Sales for the quarter ended Dec. 31 were $15.62 billion, up from $14.63 billion a year earlier.

Analysts surveyed by FactSet expected $15.48 billion.

For the full year 2025, Merck ( MRK ) expects non-GAAP EPS of $8.88 to $9.03 on sales of $64.1 billion to $65.6 billion. Analysts polled by FactSet expect non-GAAP EPS of $9.13 from sales of $67.07 billion.

Price: 88.96, Change: -10.83, Percent Change: -10.85